Mumbai, Jan 5 : Pharma major Lupin Limited (Lupin) announced the launch of its Flucytosine capsules USP, 250 mg and 500 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Novel’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s ANCOBON® Capsules, 250 mg and 500 mg.
Flucytosine Capsules USP, 250 mg and 500 mg are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus, a company statement said.
Flucytosine Capsules USP, 250 mg and 500 mg had annual sales of approximately USD 48 million in the US.
(UNI)
